• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Safety and Effect of Very Low Levels of Low-Density Lipoprotein Cholesterol on Cardiovascular Events
In conclusion, clinical trial evidence demonstrating the efficacy and safety of LDL cholesterol lowering to a very low level is essential to ascertain the benefits and risks in reducing the residual risk of vascular disease.
Source: The American Journal of Cardiology - February 1, 2013 Category: Cardiology Authors: John C. LaRosa, Terje R. Pedersen, Ransi Somaratne, Scott M. Wasserman Tags: Review Source Type: research

Between a Rock and a Hard Place: Weighing Thrombotic Risk Against Bleeding Complications
The prospect of a further reduction of thrombotic end points (stent thrombosis, acute coronary syndromes, ischemic stroke) may seem appealing and encouraging to clinicians, interventional cardiologists in particular. Be that as it may, are we willing to accept a further reduction in thrombotic events at the trade-off of increasing hemorrhagic risk?
Source: The American Journal of Cardiology - April 25, 2013 Category: Cardiology Authors: Bartosz Hudzik, Lech Polonski Tags: Readers' Comments Source Type: research

Comparison of the Efficacy and Safety of Two Rivaroxaban Doses in Acute Coronary Syndrome (from ATLAS ACS 2–TIMI 51)
In conclusion, the 2 doses of rivaroxaban reduced cardiovascular events in patients with recent acute coronary syndromes treated with antiplatelet therapies; however, the 2.5-mg dose was associated with lower mortality and fewer bleeding complications than the 5-mg dose. Thus, the addition of rivaroxaban 2.5 mg twice daily offers a more favorable balance of efficacy and safety in patients with recent acute coronary syndromes.
Source: The American Journal of Cardiology - May 28, 2013 Category: Cardiology Authors: Jessica L. Mega, Eugene Braunwald, Stephen D. Wiviott, Sabina A. Murphy, Alexei Plotnikov, Nina Gotcheva, Mikhail Ruda, C. Michael Gibson Tags: Coronary Artery Disease Source Type: research

Angina Pectoris or Myocardial Infarctions, Pulmonary Arteriovenous Malformations, Hereditary Hemorrhagic Telangiectasia, and Paradoxical Emboli
In conclusion, we suggest that in patients with untreated PAVMs, cardiac ischemia can occur because of a paradoxical embolus through PAVMs to a coronary artery.
Source: The American Journal of Cardiology - May 23, 2013 Category: Cardiology Authors: Katherine Clark, Reed E. Pyeritz, Scott O. Trerotola Tags: Miscellaneous Source Type: research

Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry SCAAR)
In conclusion, in this real world population of patients who underwent urgent or elective PCI, prasugrel was used mainly in patients with ACS, while it was avoided in patients with characteristics indicating increased bleeding risk. Mortality and bleeding rates were lower with prasugrel than clopidogrel, probably because of patient selection.
Source: The American Journal of Cardiology - October 28, 2013 Category: Cardiology Authors: Peter Damman, Christoph Varenhorst, Sasha Koul, Peter Eriksson, David Erlinge, Bo Lagerqvist, Stefan K. James Tags: Coronary Artery Disease Source Type: research

Meta-Analysis of Efficacy and Safety of Rivaroxaban Compared With Warfarin or Dabigatran in Patients Undergoing Catheter Ablation for Atrial Fibrillation
In conclusion, our study suggests that patients treated with rivaroxaban during periprocedural catheter ablation have similar rates of thromboembolic events and major hemorrhage. Similar results were seen in direct comparisons between dabigatran and rivaroxaban.
Source: The American Journal of Cardiology - June 9, 2014 Category: Cardiology Authors: Madan Raj Aryal, Anene Ukaigwe, Anil Pandit, Paras Karmacharya, Rajesh Pradhan, Naba Raj Mainali, Ranjan Pathak, Leena Jalota, Yashoda Bhandari, Anthony Donato Tags: Arrhythmias and Conduction Disturbances Source Type: research

Effects of Oral Anticoagulant Therapy in Medical In-patients ≥65 Years of Age with Atrial Fibrillation
In this retrospective cohort observational study we investigated mortality, ischemic and hemorrhagic events, in patients ≥65 years of age with atrial fibrillation (AF) consecutively discharged from an Acute Geriatric Ward in the period 2010-2013. Stroke and bleeding risk were evaluated using CHA2DS2-VASC and HAS-BLED scores. Comorbidity, cognitive status and functional autonomy were evaluated using standardized scales. Independent associations between clinical variables, including use of Vitamin K Antagonists (VKAs)-based oral anticoagulant therapy (OAT), and all-cause mortality, fatal and non-fatal ischemic and hemorrha...
Source: The American Journal of Cardiology - December 1, 2015 Category: Cardiology Authors: Mario Bo, Irene Sciarrillo, Federica Li Puma, Marco Badinella Martini, Yolanda Falcone, Marina Iacovino, Enrica Grisoglio, Elena Menditto, Gianfranco Fonte, Enrico Brunetti, Guido Maggiani, Giovanni Carlo Isaia, Fiorenzo Gaita Source Type: research

Treatment of Massive or Submassive Acute Pulmonary Embolism with Catheter Directed Thrombolysis
The presentation of acute pulmonary thromboembolism (PE) can be highly variable resulting in diagnostic challenges and management difficulties. Current guidelines suggest that therapy must be adjusted based on the severity of PE presentation. Systemic thrombolysis is the standard therapy for acute massive pulmonary embolism (PE), however systemic thrombolysis carries an estimated 20% risk of major hemorrhage, including a 3%-5% risk of hemorrhagic stroke. There are data supporting the use of catheter directed therapy (CDT) in massive and sub-massive PE, but past studies have limited its use to patients in whom systemic thro...
Source: The American Journal of Cardiology - December 31, 2015 Category: Cardiology Authors: Ashraf Mostafa, Alexandros Briasoulis, Tesfaye Telila, Kevin Belgrave, Cindy Grines Source Type: research

Treatment of Massive or Submassive Acute Pulmonary Embolism With Catheter-Directed Thrombolysis
The presentation of acute pulmonary thromboembolism (PE) can be highly variable resulting in diagnostic challenges and management difficulties. Current guidelines suggest that therapy must be adjusted based on the severity of PE presentation. Systemic thrombolysis is the standard therapy for acute massive PE; however, systemic thrombolysis carries an estimated 20% risk of major hemorrhage, including a 3% to 5% risk of hemorrhagic stroke. There are data supporting the use of catheter-directed therapy (CDT) in massive and submassive PE, but past studies have limited its use to patients in whom systemic thrombolysis has eithe...
Source: The American Journal of Cardiology - December 31, 2015 Category: Cardiology Authors: Ashraf Mostafa, Alexandros Briasoulis, Tesfaye Telila, Kevin Belgrave, Cindy Grines Tags: Review Source Type: research

Financial Implications and Impact of Pre-Existing Atrial Fibrillation on in-Hospital Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation (From the National Inpatient Database)
The objective of this study was to evaluate the financial implications and the impact of pre-existing atrial fibrillation (AF) on in-hospital outcomes in patients undergoing transcatheter aortic valve implantation (TAVI) using the Nationwide Inpatient Sample (NIS) database. We identified patients who underwent TAVI from 2011 to 2014. The primary endpoint was the effect of pre-existing AF on in-hospital mortality. Secondary endpoints included peri-procedural cardiac complications, stroke and hemorrhage requiring transfusion.
Source: The American Journal of Cardiology - March 14, 2018 Category: Cardiology Authors: Hossam Abubakar, Ahmed Salah Yassin, Emmanuel Akintoye, Khalid Bakhit, Mohit Pahuja, Mohamed Shokr, Randy Lieberman, Luis Afonso Source Type: research

Financial Implications and Impact of Pre-existing Atrial Fibrillation on In-Hospital Outcomes in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the National Inpatient Database)
The objective of this study was to evaluate the financial implications and the impact of pre-existing atrial fibrillation (AF) on in-hospital outcomes in patients who underwent transcatheter aortic valve implantation (TAVI) using the Nationwide Inpatient Sample (NIS) database. We identified patients who underwent TAVI from 2011 to 2014. The primary end point was the effect of pre-existing AF on in-hospital mortality. Secondary end points included periprocedural cardiac complications, stroke, and hemorrhage requiring transfusion.
Source: The American Journal of Cardiology - March 14, 2018 Category: Cardiology Authors: Hossam Abubakar, Ahmed S. Yassin, Emmanuel Akintoye, Khalid Bakhit, Mohit Pahuja, Mohamed Shokr, Randy Lieberman, Luis Afonso Source Type: research

Usefulness and Safety of Rivaroxaban in Patients Following Isolated Mitral Valve Replacement With A Mechanical Prosthesis
Rivaroxaban has previously been tested in experimental and animal models with encouraging results. We prospectively selected 7 patients between May 2017 and January 2018 who underwent isolated mitral valve replacement with a mechanic prosthesis and had unstable INR control at least 3 months after surgery. An intervention of rivaroxaban 15 mg was then administered twice daily for a period of 90 days. No patient presented intracardiac thrombus, reversible ischemic neurological deficit, ischemic or hemorrhagic stroke, hospitalization or death during 3 months of follow-up.
Source: The American Journal of Cardiology - July 15, 2018 Category: Cardiology Authors: Andr é R Durães, Yasmin de S L Bitar, Maria Luiza G Lima, Caroline C Santos, Igor S Schonhofen, José Admirço L Filho, Leonardo Roever Source Type: research

Comparison of In-hospital Outcomes of Patients With-vs-Without Ischemic Cardiomyopathy Undergoing Left Ventricular Assist Device Placement
The objective of this study was to evaluate the impact of heart failure (HF) etiology (ischemic cardiomyopathy (IC) vs. non-ischemic cardiomyopathy (NIC)) on in-hospital outcomes in patients undergoing left ventricular assist device (LVAD) placement using the Nationwide Inpatient Sample (NIS) database. We identified patients who underwent LVAD placement from 2011 to 2014. The primary endpoint was the effect of ICM on in-hospital mortality. Secondary endpoints included peri-procedural vascular complications requiring surgery, post-operative myocardial infarction, stroke and hemorrhage requiring transfusion.
Source: The American Journal of Cardiology - November 20, 2018 Category: Cardiology Authors: Hossam Abubakar, Ahmed Subahi, Oluwole Adegbala, Ahmed S Yassin, Emmanuel Akintoye, Ahmed Abdulrahman, Abdelrahman Ahmed, Adedotun Alade, Mohit Pahuja, Luis Afonso Source Type: research

Comparison of In-Hospital Outcomes of Patients With-Versus-Without Ischemic Cardiomyopathy Undergoing Left Ventricular Assist Device Placement
The objective of this study was to evaluate the impact of heart failure (HF) etiology (ischemic cardiomyopathy [ICM] versus nonischemic cardiomyopathy) on in-hospital outcomes in patients undergoing left ventricular assist device (LVAD) placement using the Nationwide Inpatient Sample database. We identified patients who underwent LVAD placement from 2011 to 2014. The primary end point was the effect of ICM on in-hospital mortality. Secondary end points included periprocedural vascular complications requiring surgery, postoperative myocardial infarction, stroke, and hemorrhage requiring transfusion.
Source: The American Journal of Cardiology - November 20, 2018 Category: Cardiology Authors: Hossam Abubakar, Ahmed Subahi, Oluwole Adegbala, Ahmed S. Yassin, Emmanuel Akintoye, Ahmed Abdulrahman, Abdelrahman Ahmed, Adedotun Alade, Mohit Pahuja, Luis Afonso Source Type: research

Cardiovascular Outcomes and All-cause Mortality Following Measurement of Endogenous Testosterone Levels
We examined whether low total testosterone levels are associated with stroke (ischemic and hemorrhagic), myocardial infarction (MI), venous thromboembolism (VTE), and all-cause mortality among adult men. We conducted a cohort study in the Central Denmark Region (20002015). We included all men with a first-ever laboratory testosterone result and computed the 5-year risks of cardiovascular outcomes and all-cause mortality.
Source: The American Journal of Cardiology - March 7, 2019 Category: Cardiology Authors: Kasper Adelborg, Thomas B øjer Rasmussen, Helene Nørrelund, J Bradley Layton, Henrik Toft Sørensen, Christian Fynbo Christiansen Source Type: research

Pages: 1  2  3